Get the latest news, insights, and market updates on ACON (Aclarion, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Aclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS)
Featured article strengthens growing body of clinical evidence for Nociscan by highlighting a successful case studySpecial Pain issue features breakthrough innovations shaping the future of spine careIJSS publishes over 150 articles annually representing 40+ nations BROOMFIELD, Colo., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algor Dec 4, 2025 - $ACON
Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.
Proven commercial leader with 20+ years of experience driving revenue growth and market adoption for early-stage and high-growth MedTech companiesStrong track record of launching breakthrough technologies across spine, neurosurgery and pain managementStrengthens Aclarion’s commercial execution as the Company expands adoption and payer engagement across the Eastern U.S. BROOMFIELD, Colo., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a heal Dec 2, 2025 - $ACON
Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion
Marks Aclarion’s first commercial sales hire with seasoned HealthTech leader and proven track record of advancing musculoskeletal imaging and spinal surgeryExperiencing strong commercial traction in UK as first market worldwide with private insurers covering NociscanNociscan reimbursed by three of top four private insurers in UK, giving access to more than 5.2 million covered lives BROOMFIELD, Colo., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, AC Nov 5, 2025 - $ACON
Aclarion Wins “Rising Star” at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH
Company previously announced it was selected as a finalist from more than 1,800 submissions Award win underscores growing impact of Aclarion’s breakthrough Nociscan solution for chronic low back pain BROOMFIELD, Colo., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back Oct 22, 2025 - $ACON
Aclarion Provides Corporate Update Highlighting Market Expansion as CLARITY Trial Advances Toward Key Data Catalyst
Debt-free balance sheet with $13.3 million in cash as of today ($15.11 per share fully diluted) providing strategic flexibility for continued commercial growth Nociscan scan volumes increase +89% year-over-year with third consecutive quarter of record utilization across U.S., U.K., and E.U. markets CLARITY pivotal trial progressing on schedule and early 3-month readouts expected Q2 2026 as AI-driven disc pain biomarker validation continues Webcast scheduled for October 20th at 12:00 pm PT at the Oct 14, 2025 - $ACON
Aclarion Announces Use of MR Spectroscopy for identifying Biomarkers of Discogenic Pain highlighted at Global Neuroscience Conference
Panel discussion featured at the International Society of Pain and Neuroscience (ISPN) Annual Meeting in London titled United to Conquer Pain Session Co-Moderator Doug Beall, M.D. underscored that disc chemistry is the critical biomarker for diagnosing the leading cause of chronic low back pain Nociscan® combines MR Spectroscopy and proprietary AI algorithms to deliver data-driven insights that inform treatment decisions to improve patient outcomes BROOMFIELD, Colo., Oct. 13, 2025 (GLOBE NEWSWIR Oct 13, 2025 - $ACON
Aclarion to Present at the LD Micro Main Event XIX
Presentation on Monday, October 20, 2025 at 12:00 PM PTBroomfield, Colorado--(Newsfile Corp. - October 9, 2025) - Aclarion, Inc. (NASDAQ: ACON) (NASDAQ: ACONW) ("Aclarion" or the "Company"), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that it will be presenting at the 19th Annual Main Event on Monday, October 20, 2025 at 12:00 PM PT at the... Oct 9, 2025 - $ACON
Aclarion Honored as Finalist for the 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH
Company recognized for breakthrough Nociscan solution for chronic low back pain, one of the most widespread health challengesBROOMFIELD, Colo., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced its selection as a finalist in the Rising Star - Clin Oct 7, 2025 - $ACON
Aclarion Presents at LSI Europe ’25 Highlighting Nociscan Technology and Key Value Drivers
BROOMFIELD, Colo., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced its recent presentation at LSI Europe ’25 which is now available to investors and stakeholders. The full presentation is available for on-demand viewing here: Replay Link During Oct 1, 2025 - $ACON
First Patients Enrolled at UHealth – University of Miami in Aclarion’s Pivotal CLARITY Trial
Enrollment remains on track with internal interim results expected in Q2 2026Randomized study to evaluate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging bi Sep 25, 2025 - $ACON
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple